Citizens Jmp Reaffirms Market Outperform Rating for TuHURA Biosciences (NASDAQ:HURA)

TuHURA Biosciences (NASDAQ:HURA)‘s stock had its “market outperform” rating restated by Citizens Jmp in a report released on Tuesday,Benzinga reports. They currently have a $9.00 price target on the stock. Citizens Jmp’s price target points to a potential upside of 294.74% from the stock’s current price.

HURA has been the topic of several other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Friday, July 17th. Citigroup began coverage on shares of TuHURA Biosciences in a report on Monday, April 27th. They issued an “outperform” rating for the company. Finally, Wall Street Zen downgraded shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a research report on Sunday, May 31st. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

TuHURA Biosciences Stock Down 7.7%

Shares of TuHURA Biosciences stock opened at $2.28 on Tuesday. The stock’s fifty day moving average is $2.29 and its 200-day moving average is $2.02. The firm has a market capitalization of $145.19 million, a PE ratio of -4.22 and a beta of -0.01. TuHURA Biosciences has a 12-month low of $0.41 and a 12-month high of $3.43.

TuHURA Biosciences (NASDAQ:HURA) last announced its earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. Analysts expect that TuHURA Biosciences will post -0.56 EPS for the current year.

Institutional Investors Weigh In On TuHURA Biosciences

Several hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in TuHURA Biosciences in the 3rd quarter worth about $26,000. JPMorgan Chase & Co. acquired a new position in shares of TuHURA Biosciences in the 2nd quarter valued at about $27,000. Invesco Ltd. acquired a new position in shares of TuHURA Biosciences in the 2nd quarter valued at about $30,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of TuHURA Biosciences in the second quarter worth approximately $31,000. Finally, Bank of America Corp DE purchased a new stake in shares of TuHURA Biosciences in the fourth quarter worth approximately $59,000. 0.62% of the stock is owned by hedge funds and other institutional investors.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics using high?dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first?in?class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.